GTx "buy"

06/26/07 - Lazard Capital Markets

NEW YORK, June 26 (newratings.com) - Analysts at Lazard Capital maintain their "buy" rating on GTx Inc (GTXI). The target price is set to $28.

In a research note published this morning, the analysts mention that the LCM survey indicates that Acapodene has the potential to generate significant sales for usage in either the ADT or hg-PIN market, if approved. The survey indicates that the Hg-PIN awareness has risen among urologists, the analysts add. The physicians, involved in the survey, project aggressive penetration of more than 50% in the ADT and hg-PIN indications during the second year of launch, according to Lazard Capital.